XBiome and Australia's ZoHealth Announce Strategic Partnership to Advance Dual-Engine Global Expansion

Recently, the strategic cooperation signing ceremony between Xbiome Co. Ltd. and ZoHealth was grandly held at the headquarters office of Xbiome in Shenzhen, China. Dr. Tan Yan, Co-founder and CEO of Xbiome, and Mr. Michael Mason, CEO of ZoHealth, signed the Strategic Cooperation Framework Agreement, marking the beginning of collaboration between the two parties around...Development of Human Intestinal Microecology, Precision Nutrition, and Health Product DevelopmentThe in-depth cooperation has officially begun.

Figure: Scene of the signing ceremony

The signing ceremony invited leaders from relevant government departments and industry associations of China and Australia:Mr. Xue Yuanpeng, Deputy Director of the Investment Promotion Department of Shenzhen Chamber of Commerce for Import and Export, Mr. Lin Huai, Chief Commercial Representative of the Australian Trade and Investment Commission in Shenzhen at the Australian Consulate General in Guangzhou, Ms. Huang He, President of Shenzhen Health Industry Development Promotion Association, Ms. Huang Ying, Secretary General of Shenzhen Health Industry Development Promotion Association, and representatives of both enterprise teams.Witnessed the event together. All parties then held a discussion.

According to the introduction, one of the core projects of this cooperation between the two parties is the ZoHealth market and product team.Based on the overseas market demands in countries like Australia and the United States, a series of probiotic products targeting gut health regulation and weight management have been launched, centered around Xbiome's star patented strains.In addition, the two parties will also engage in technical cooperation such as intestinal microbiome sequencing based on Xbiome's AI microbiome research and product development platform, as well as subsequent development of health and wellness products.

Figure: Scene of the signing ceremony

The signing of this strategic cooperation framework agreement, and the gradual implementation of the aforementioned cooperative projects, marks Xbiome's official integration into both the pharmaceutical and broader health sectors."Dual-Engine Going Global"——Following multiple collaborations with global pharmaceutical giants on drug research,First Global Commercial Collaboration Achieved Using Comprehensive Health Products and Solutions；Set a new benchmark for the development model of Shenzhen's biotechnology innovation enterprises.

Against the backdrop of globalization and the environment of China's pharmaceuticals, biotech, and healthcare industry, the strategic significance of Chinese biotech companies expanding their products overseas is immense, serving as a core indicator to evaluate a company’s R&D and commercialization capabilities. In terms of policy, governments at all levels actively encourage companies to "go global" and explore international markets. In the biotech sector, the country has also introduced a series of policies to support companies in innovating, enhancing core competitiveness, and promoting the globalization of China's biotech industry.

Xbiome's collaboration with ZoHealth aligns perfectly with the trends of the times and industry development. As an upstream provider of innovative probiotic strains, product solutions, and advanced technologies in gut microbiome research, Xbiome will achieve deep complementarity with ZoHealth's strengths in global market operations.Jointly provide higher-quality health products to consumers worldwide,Promote innovative development in fields such as the human intestinal microbiome and precision nutrition.

Figure: ZoHealth CEO Mr. Mason delivers a speech

Mr. Mason, CEO of ZoHealthSaid: "We are very pleased to reach a strategic cooperation with Xbiome. We believe that, with the help of Xbiome's excellent probiotics R&D, ZoHealth is confident in creating more scientifically evidenced innovative health products to contribute to the health of global consumers, especially in gut health management."

The figure shows Xbiome Co. Ltd. Co-founder and CEO Dr. Tan Yan (left) giving a speech.

Xbiome Co-Founder and CEO, Dr. Tan YanSaid: "Thank you to international health partner ZoHealth for trusting Xbiome. Xbiome's original strains have received multiple patent protections and possess innovative functions along with pharmaceutical-grade mechanism research and functional validation, enabling the company to provide top-tier products, technologies, and solutions to partners in China and globally. This collaboration marks Xbiome's official entry into the international market in the health direction, achieving a 'dual-engine go-global' strategy of pharmaceuticals + health.We are confident in safeguarding and improving human health globally with Chinese biotechnology.”

The human intestinal microbiota, probiotics, and precision nutrition are becoming focal points of attention in the global biotechnology and international trade sectors. All parties involved in the signing ceremony conducted in-depth discussions on hot topics within the industry.Mr. Xue YuanpengXbiome's achievements in human gut microbiota research and product development in recent years are exciting. This collaboration between the two parties will lead China's biotechnology to the world.Mr. Lin HuaiAustralia has a strong foundation and abundant achievements in both the life sciences and industry sectors. It is expected that the cooperation between Xbiome and ZoHealth will become an exemplary model of collaboration between Australian and Chinese biotech companies, benefiting the health of people worldwide.Ms. Huang HeRepresentatives stated that the Shenzhen Health Industry Development Promotion Association is committed to helping biotech companies such as Xbiome and ZoHealth build platforms and connect resources, supporting the rapid and healthy development of enterprises, industries, and the sector. All parties agreed that innovative technology will lead the future of global health, and highly praised this collaboration as an important measure in line with current trends.

Figure: Mr. Xue Yuanpeng, Deputy Minister of the Investment Promotion Department of Shenzhen Municipal Commission of Commerce, delivers a speech.

Shown in the picture are the Australian Consulate-General in Guangzhou and the Australian Trade and Investment Commission.
Speech by Mr. Lin Huai, Chief Commercial Representative of the Shenzhen Representative Office

Figure: Ms. Huang He, Executive President of Shenzhen Health Industry Development Promotion Association, delivers a speech.

-End-